News

The UME module adds to the list of ophthalmic diseases available in the dataset.

The COVID-19 pandemic changed medicine forever, and now scientists are forging a new path for healthcare in the future, including in ophthalmology.

According to researchers at Waseda University in Japan, the proposed device can measure electrical potentials from different places in the retina simultaneously, which is useful in diagnosing eye diseases.

According to the company, its Phase 3 program enrolled 1,984 patients across COAST and ShORe trials. Topline data from both pivotal trials are expected in 2025.

Understanding how the intricate networks of blood vessels in the eye and brain are formed ultimately could inspire new treatments for conditions like diabetic retinopathy and stroke.

Investigators undertook a secondary analysis of the effects of long-term, low-dose aspirin in over 3,000 older adults who satisfied the inclusion criteria in the Aspirin in Reducing Events in the Elderly–AMD (ASPREE-AMD) study.

Only symptom in 1 case was conjunctivitis.

Metformin, an anti-diabetes drug, may partially suppress the formation of neovascular tufts on the retinal surface by blocking the mTORC1 signaling pathway

A retrospective study found that the frequency of ocular metastases was relatively low.

The agency approved Yesafili (Biocon Biologics) and Opuviz (Samsung Bioepis, Biogen) as biosimilars to Eylea (Regeneron Pharmaceuticals).

Durga Borkar, MD, MMCi, spoke with Modern Retina about the quality data (Qdata) gathered on geographic atrophy as well as the GATHER 1 and GATHER 2 data she presented at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

Ash Abbey, MD, spoke with Modern Retina at the 2024 Retina World Congress in Fort Lauderdale, Florida. He shared details about the week 32 data from the phase 2 DAVIO-2 trial for EYP-1901.

J. Fernando Arevalo, MD, PhD, FACS, FASRS, spoke about a recent study looking at what happens to patients with diabetic retinopathy who are lost to follow-up. He presented this research at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

David Almeida, MD, PhD, MBA, shared insights on the surgical tools he uses in his practice at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

Researchers note the G90D mutation in rhodopsin is known to produce background electrical noise to desensitize rods, but the nature of the ‘noise’ and its precise molecular source have not been resolved for almost 30 years.

The company reported that statistically significant data was found supporting ANX007’s ability to provide vision loss protection in patients with geographic atrophy.

The campaign will encourage, educate and empower the public to include vision and eye health as a part of their healthcare by asking them to share how eye care services and exams improved their vision and their daily lives.

According to ophthalmologists at the Colorado University School of Medicine, discussing mental well-being is a key part of effective treatment and improving care for patients.

At this year's ARVO meeting, Edmund Tsui, MD, presented a paper on the analysis of anterior chamber inflammation through automated quantitative assessment of swept-source anterior segment OCT images.

At this year's ARVO meeting, Roger Goldberg, MD, presented a paper on hard exudates and their resolution in patients with diabetic macular edema treated with either faricimab or 2 mg aflibercept.

At this year's ARVO meeting, Daniela Ferrara, MD, PhD, FASRS, presented a paper on predicting functional outcomes for different treatment durations of faricimab in diabetic macular edema.

At this year's ARVO meeting, Irene Santiago Tierno, MS, talked with Ophthalmology Times about the paper she presented on how abnormal subendothelial matrix exacerbates choroidal endothelial cell death in early age-related macular degeneration.

Dilsher S. Dhoot, MD, shared details about the Week 52 safety and efficacy data from the US phase 1 clinical trial of sustained-release axitinib hydrogel implant (OTX-TKI) for neovascular age-related macular degeneration at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene.

At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Niranchana Manivannan, PhD. She spoke about the poster presentation, "Feasibility and clinical efficacy of an OCT B-scan of interest tool."

Professor Paulo-Eduardo Stanga spoke with Modern Retina about a new wearable assistance device at the 2024 Retina World Congress meeting held in Fort Lauderdale, Florida

Researchers at the University of Missouri School of Medicine have conducted a study in a humanized mouse model to show that infections can occur deep inside the eye by penetrating the blood-retinal barrier.

According to the company, GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals.